Log in to save to my catalogue

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administrati...

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administrati...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1504639511

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12 -receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)

About this item

Full title

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12 -receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)

Publisher

New York, NY: Elsevier Inc

Journal title

The American heart journal, 2010-07, Vol.160 (1), p.65-72

Language

English

Formats

Publication information

Publisher

New York, NY: Elsevier Inc

More information

Scope and Contents

Contents

Despite current dual-antiplatelet therapy with aspirin and clopidogrel, adverse clinical events continue to occur during and after percutaneous coronary intervention (PCI). The failure of clopidogrel to provide optimal protection may be related to delayed onset of action, interpatient variability in its effect, and an insufficient level of platelet...

Alternative Titles

Full title

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12 -receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_1504639511

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1504639511

Other Identifiers

ISSN

0002-8703

E-ISSN

1097-6744

DOI

10.1016/j.ahj.2010.04.008

How to access this item